A Comparison of the Oncological Outcomes After Breast-Conserving Surgery With or Without Latissimus Dorsi Myocutaneous Flap Reconstruction for Breast Cancer

Clin Breast Cancer. 2022 Feb;22(2):e184-e190. doi: 10.1016/j.clbc.2021.06.005. Epub 2021 Jun 15.

Abstract

Background: There is little information on the oncological outcomes of breast-conserving surgery (BCS) with immediate reconstruction using a latissimus dorsi myocutaneous flap (LDMF) for breast cancer compared with BCS alone.

Patients and methods: We conducted a retrospective cohort study from a single institution comparing the margin positivity rates after initial surgery, re-excision rates, and local recurrence (LR) between BCS with immediate LDMF reconstruction (n = 145) and BCS alone (n = 1040) performed from 2012 to 2017 for newly diagnosed stage 0-3 breast cancer.

Results: The positive rates of surgical margin after initial surgery were significantly lower in the BCS with LDMF group than in the BCS alone group (4.1 vs. 10.8%; P = .006). There were no marked differences in the re-excision rates between the BCS with LDMF and BCS alone groups (P = .1). At a median follow-up of 61 months, the surgical method (BCS with LD vs. BCS alone) was not associated with the LR-free survival after adjusting for various clinicopathologic factors (P = .8).

Conclusion: Our findings suggest that BCS with immediate LDMF reconstruction is oncologically safe for breast cancer compared with BCS alone. However, further studies are needed.

Keywords: Breast Cancer; Breast reconstruction; Breast-Conserving Surgery; Latissimus dorsi flap; Local recurrence.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Breast Neoplasms / pathology
  • Breast Neoplasms / surgery*
  • Female
  • Humans
  • Mammaplasty / methods
  • Mastectomy, Segmental / methods*
  • Middle Aged
  • Myocutaneous Flap / transplantation*
  • Patient Satisfaction
  • Retrospective Studies
  • Superficial Back Muscles / transplantation*
  • Surgical Flaps*
  • Time Factors